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In-feed bambermycin medication induces 
anti-inflammatory effects and prevents parietal 
cell loss without influencing Helicobacter suis 
colonization in the stomach of mice
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and Freddy Haesebrouck1*
Abstract 
The minimum inhibitory concentration of bambermycin on three porcine Helicobacter suis strains was shown to 
be 8 μg/mL. The effect of in-feed medication with this antibiotic on the course of a gastric infection with one of 
these strains, the host response and the gastric microbiota was determined in mice, as all of these parameters may 
be involved in gastric pathology. In H. suis infected mice which were not treated with bambermycin, an increased 
number of infiltrating B-cells, T-cells and macrophages in combination with a Th2 response was demonstrated, as well 
as a decreased parietal cell mass. Compared to this non-treated, infected group, in H. suis infected mice medicated 
with bambermycin, gastric H. suis colonization was not altered, but a decreased number of infiltrating T-cells, B-cells 
and macrophages as well as downregulated expressions of IL-1β, IL-8M, IL-10 and IFN-γ were demonstrated and the 
parietal cell mass was not affected. In bambermycin treated mice that were not infected with H. suis, the number of 
infiltrating T-cells and expression of IL-1β were lower than in non-infected mice that did not receive bambermycin. 
Gastric microbiota analysis indicated that the relative abundance of bacteria that might exert unfavorable effects on 
the host was decreased during bambermycin supplementation. In conclusion, bambermycin did not affect H. suis 
colonization, but decreased gastric inflammation and inhibited the effects of a H. suis infection on parietal cell loss. 
Not only direct interaction of H. suis with parietal cells, but also inflammation may play a role in death of these gastric 
acid producing cells.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Helicobacter suis is a Gram-negative, spiral-shaped bacte-
rium found in the stomach of up to 90% of pigs at slaugh-
ter age, causing gastritis and a decreased daily weight 
gain [1, 2]. In addition, infection with this bacterium has 
been associated with ulceration of the non-glandular 
part of the porcine stomach, most likely through induc-
tion of gastric acid secretion alterations and by influenc-
ing the gastric microbiota [3]. Apart from pigs, H. suis 
is the most prevalent gastric non-H. pylori Helicobacter 
(NHPH) species in humans. H. suis infection in humans 
has been associated with gastritis, peptic ulcers and 
mucosa-associated lymphoid tissue (MALT) lymphoma 
[4]. Direct or indirect contact with H. suis infected pigs 
or consumption of contaminated water or raw or under-
cooked pork may be a source of human infection [5]. 
Since rodent models are easily colonized with H. suis, the 
role of wild mice as vectors might also be considered.
In general, Helicobacter sp. infected human patients 
are treated with a combination of a proton pump inhibi-
tor and two or three antibiotics selected from clarithro-
mycin, amoxicillin, metronidazole, tetracycline and/
or levofloxacin [6]. A similar therapeutic protocol is not 
indicated in H. suis infected pigs since this is expensive, 
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labor intensive and antibiotic use may favor spread of 
antimicrobial resistance in pathogens as well as in bacte-
ria belonging to the microbiota [7]. In addition, no vac-
cine formulation is available which completely protects 
pigs against H. suis infection [8], making development of 
an alternative therapy desirable [4]. Recently, an inhibi-
tory action of bambermycin, a glycolipid antibiotic, has 
been described towards H. pylori strains [9]. As H. pylori 
is closely related to H. suis, it can be hypothesized that 
bambermycin might inhibit H. suis as well.
Bambermycin (synonyms: flavophospholipol, moeno-
mycin, flavomycin) disrupts bacterial cell wall synthesis 
[10] and is mainly active against Gram-positive bacteria 
and to some extent against Gram-negative bacteria such 
as Pasteurella sp., Brucella sp. and H. pylori [10]. Due to 
its high molecular weight, bambermycin is not absorbed 
in the gastro-intestinal tract after oral administration. 
Until 2006, it was used as a growth promoter in animal 
feed in the European Union [10]. The growth promot-
ing effects of bambermycin supplementation have been 
linked with a better equilibrium of the gastro-intestinal 
microbiota which might be due to a reduced colonization 
of pathogens, such as Salmonella enterica, Clostridium 
perfringens and Fusobacterium spp. [10–13], while bacte-
ria considered to have beneficial effects, such as Lactoba-
cillus spp., are not affected. The effect on S. enterica and 
C. perfringens in the intestinal tract, however, contrasts 
with the relative insensitivity of these species to bam-
bermycin in vitro [10]. Although bambermycin was fre-
quently used as a feed additive for over 50 years, acquired 
resistance, transfer of resistance or cross-resistance with 
other antimicrobials has not yet been reported [10]. It 
has been described that bambermycin selectively inhibits 
the growth of Escherichia coli and S. enterica harboring 
resistance plasmids and decreases the conjugation trans-
fer frequency of resistance plasmids in E. coli, S. enterica 
and Staphylococcus aureus [14–16].
The main objective of this study was to determine the 
effect of bambermycin supplementation on the course 
of a H. suis infection, the host response and the gastric 
microbiota, as all these parameters may be involved in 
gastric pathology. BALB/c mice were used as an experi-
mental model, as in previous studies we showed that 
these rodents can easily be colonized with H. suis, result-
ing in gastritis, epithelial cell hyperproliferation and 
necrosis of parietal cells [17], which are also representing 
the main characteristics of a human and porcine infec-
tion with this agent.
A second objective of our study was to determine if in-
feed medication with bambermycin might be useful to 
control H. suis infections in pigs.
Materials and methods
Minimum inhibitory concentration (MIC) of bambermycin 
on H. suis strains
H. suis strains
Helicobacter suis strains HS1, HS8 and P13/26 were iso-
lated from the gastric mucosa of pigs from different herds 
according to the method described by Baele et  al. [18]. 
The strains were shown to be genetically different by 
multilocus sequence typing [19].
All strains were cultured under biphasic and micro-
aerobic conditions at 37 °C. The biphasic medium con-
sisted of Brucella agar (BD, Franklin Lakes, New Jersey, 
USA) supplemented with 20% fetal calf serum (GE 
Healthcare Life Sciences, Logan, USA), 5  mg ampho-
tericin B/l (Sigma-Aldrich, Saint Louis, Missouri, USA), 
Campylobacter selective supplement (Oxoid) and Vitox 
supplement (Oxoid). The pH of the agar was adjusted 
to 5 by adding HCl to a final concentration of approxi-
mately 0.05%. Finally, Brucella broth (BD, pH 5) was 
added on top. Isolates were passaged twice to ensure 
reliable growth. After incubation, the bacteria were har-
vested and the concentration was determined using an 
improved Neubauer counting chamber (Sigma-Aldrich).
Determination of MIC‑values of bambermycin
The MIC of bambermycin for H. suis strains HS1, HS8 
and P13/26 was determined according to the method 
described by Vermoote et  al. [20]. In brief, a combined 
Brucella agar and broth dilution method in 24-well 
plates was used. Twofold dilutions of bambermycin 
 (flavomycin®, Huvepharma, Antwerp, Belgium) were 
added to the agar and broth, with final concentrations 
ranging from 0.03 to 128 μg/mL. In total, 5 × 107 bacte-
ria/mL were added to the broth and incubated during 
48  h under microaerobic conditions. After incubation, 
H. suis was quantified using a quantitative real-time PCR 
(qPCR) where the ureA gene was amplified. The MIC 
was determined as the lowest concentration of bamber-
mycin for which ∆Ct was at least 1  Ct higher than ∆cCt 
(∆Ct = Ct after incubation − Ct before incubation of the 
bambermycin exposed strains; ∆cCt = Ct after incuba-
tion − Ct before incubation of the controls;  Ct = threshold 
cycle value) [20]. This is the lowest concentration of bam-
bermycin with at least 50% less bacterial growth com-
pared to controls without bambermycin.
Staphylococcus aureus ATCC 29213 was included as a 
reference strain. For this strain, 4 different MIC assays 
were performed: the broth microdilution procedure 
according to the CLSI standards, the method described 
by Butaye et al. [21, 22], the H. suis susceptibility assay 
conditions at pH 5 and the same conditions but at pH7.
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Effect of bambermycin supplemented diet on a H. suis 
infection in mice
Ethic statement
The in  vivo experimental protocol was approved by the 
Ethical Committee of the Faculty of Veterinary Medicine, 
Ghent University, Belgium (EC 2015/131; November 
 17th, 2015).
Animals and experimental design
Forty-eight specific-pathogen-free (SPF) female, 5-week-
old BALB/cOlaHsd mice were purchased from Harlan 
NL (Horst, the Netherlands). All animals tested negative 
for presence of Helicobacter spp. by the use of a Helico-
bacter genus specific PCR. The animals were randomly 
divided into 6 groups, each consisting of 8 mice. The 
groups were assigned as followed: non-H. suis infected 
mice fed a control diet without bambermycin (H. suis-
negative control group; group 1), non-H. suis infected 
mice fed a 32  ppm bambermycin supplemented diet 
(group 2), non-H. suis infected mice fed a 64 ppm bam-
bermycin supplemented diet (group 3), H. suis infected 
mice fed a control diet without bambermycin (H. suis-
positive control group, group 4), H. suis infected mice fed 
a 32 ppm bambermycin supplemented diet (group 5) and 
H. suis infected mice fed a 64  ppm bambermycin sup-
plemented diet (group 6). For each group, the mice were 
housed on autoclaved soft wood shavings in 2 separate 
filter-top cages to minimize cage-effect (i.e. four mice 
per cage). Drinking water was provided ad  libitum. The 
animals were monitored several times a day during the 
whole experiment. Enrichment was provided in the form 
of paper tissues, mouse houses and other homemade 
available enrichment products. All animals were exposed 
to a 12:12 light:dark cycle in the same stable under con-
trolled environmental conditions.
One week after arrival, groups 4–6 were inoculated 
twice with H. suis strain HS1 with a 48 h interval. Under 
brief isoflurane anesthesia and using a ball-tipped gavage 
needle, 350 μL Brucella broth (pH 5) containing 7 × 107 
bacteria of HS1 was administered intragastrically. Groups 
1–3 received an equal volume of Brucella broth (pH 5). 
The mice were held in an upright position until they 
regained consciousness, to minimize the risk of reflux. 
Starting from 1 week after inoculation, the mice were fed 
ad libitum a control diet (groups 1 and 4), a diet supple-
mented with 32 ppm bambermycin (groups 2 and 5) or 
a diet supplemented with 64 ppm bambermycin (groups 
3 and 6). The bambermycin supplemented diets were 
identical to the control diet, with the exception of being 
supplemented with 32 or 64 ppm bambermycin and with 
a variable amount of corn starch, used to correct minor 
differences in the energy content (Research Diets Inc., 
New Brunswick, USA). Finally, 9 weeks after the second 
inoculation, the mice were euthanized by cervical dislo-
cation under deep isoflurane anesthesia. The stomachs 
were removed and opened along the major curvature. 
Four longitudinal strips were taken from the forestom-
ach to the duodenum. One strip was fixed in 10% phos-
phate-buffered formalin and used for histopathology and 
immunohistochemistry. The other strips were used for 
DNA- and RNA-extraction.
Histopathology and immunohistochemistry
The formalin fixed longitudinal strip from the stomach 
was embedded in paraffin, sectioned at 5 μm, rehydrated 
and deparaffinized.
For each stomach, one of the sections was stained with 
haematoxylin and eosin, dehydrated and finally mounted 
with a coverslip for light microscopic evaluation. The 
severity of gastritis was scored according to the updated 
Sydney system with some modifications [1, 23]. Both 
diffuse infiltration with inflammatory cells and the pres-
ence of lymphoid aggregates and lymphoid follicles in the 
mucosa and submucosa were taken into consideration. 
The diffuse infiltration of mononuclear and polymorpho-
nuclear cells was scored as follows: score 0 for absence 
of infiltration, score 1 for mild infiltration, score 2 for 
moderate infiltration and score 3 for marked infiltra-
tion. In addition, the formation of lymphoid follicles was 
scored as follows: score 0 for absence of lymphoid aggre-
gates, score 1 for presence of a small number of lymphoid 
aggregates (n < 5), score 2 for a large number of lymphoid 
aggregates (n > 5) and/or the presence of 1 organized 
lymphoid follicle and score 3 for the presence of at least 2 
organized lymphoid follicles. Based on the scoring of the 
diffuse infiltration with inflammatory cells and the pres-
ence of lymphoid aggregates and lymphoid follicles, an 
overall gastritis score was obtained. Therefore, the aver-
age score was calculated for each group. When an overall 
score of 0 < n ≤ 1; 1 < n ≤ 2 or 2 < n ≤ 3 was obtained, the 
gastritis was considered as mild, moderate and severe, 
respectively.
The other sections were used to determine H. suis 
colonization density, to study the presence of lymphoe-
pithelial lesions, to analyze the number of infiltrating 
T-cells, B-cells and macrophages and, finally, to deter-
mine the number of parietal cells, necrotic cells and rep-
licating cells. After rehydration and deparaffinization, 
heat-induced antigen retrieval was performed in citrate 
buffer (pH 6) using a microwave oven. Slides were incu-
bated with 3%  H2O2 in methanol (5 min) to block endog-
enous peroxidase activity and 30% goat serum (30 min) 
to block non-specific reactions. Negative controls to 
confirm the specificity of the secondary antibodies were 
obtained by incubating the sections without the primary 
antibodies.
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Helicobacter suis colonization was visualized using 
a polyclonal genus-specific rabbit anti-H. pylori anti-
body (1/320; DakoCytomation, Glostrup, Denmark). For 
detection of infiltrating T- and B-cells, a polyclonal rabbit 
anti-CD3 antibody (1/100; DakoCytomation, Glostrup, 
Denmark) and a polyclonal rabbit anti-CD20 antibody 
(1/25; Thermo Scientific, Fremont, USA) were used, 
respectively. Incubation with primary antibodies directed 
against Helicobacter, CD3 and CD20 was followed by 
incubation with a biotinylated goat anti-rabbit IgG anti-
body (1/500; DakoCytomation). After rinsing, the sec-
tions were incubated with a streptavidin–biotin-HRP 
complex (Agilent Technologies, Santa Clara, California, 
USA) and the color was developed with diaminobenzi-
dine tetrahydrochloride (DAB) and  H2O2.
To determine the infiltrating macrophages, a primary 
antibody directed against the F4/80 surface marker 
(1/50; Santa Cruz Biotechnology, Santa Cruz, USA) was 
used. Detection was done using a rat ABC staining sys-
tem (Santa Cruz Biotechnology). Apoptotic cells were 
identified by immunohistochemical staining using a rab-
bit polyclonal antibody directed against active caspase-3 
and an anti-rabbit HRP-AEC cell and tissue staining kit 
(R&D Systems, Minneapolis, USA). Replicating cells were 
identified using a mouse monoclonal anti-Ki67 antibody 
(1/25; Novocastra Laboratories Ltd, Newcastle upon 
Tyne, UK) and a biotinylated goat anti-mouse IgG anti-
body (1/200; DakoCytomation). Subsequent visualization 
was done as described for CD3 and CD20 staining. Pari-
etal cells were identified by immunohistochemical stain-
ing for the hydrogen potassium ATPase using a mouse 
monoclonal antibody (1/200; Abcam Ltd, Cambridge, 
UK) and a biotinylated goat anti-mouse IgG antibody 
(1/200; DakoCytomation). Subsequent visualization was 
done as described for CD3 and CD20 staining. A mono-
clonal mouse anti-cytokeratin antibody (1/50; DakoCyto-
mation) was used to highlight lymphoepithelial lesions.
Helicobacter suis colonization density was scored 
according to the updated Sydney system [23]. T-cells, 
B-cells, macrophages, apoptotic cells, replicating cells 
and parietal cells were counted in five randomly chosen 
high power fields (magnification: 400×). The average 
number of positive cells per high power field was then 
calculated for each mouse.
Quantification of H. suis by real time PCR
DNA was extracted from the second gastric tissue strip 
using the Isolate II Genomic DNA  Kit® (Bioline, Taun-
ton, USA), according to the instructions of the manufac-
turer. The presence of H. suis DNA was determined using 
a species-specific, quantitative real time (RT)-PCR based 
on the ureA gene [24]. The copy number of the obtained 
amplicons was calculated and converted to the number 
of H. suis bacteria per mg gastric tissue, by including 
Tenfold dilutions of an external standard consisting of a 
1236 bp segment of the ureAB gene cluster from H. suis 
strain HS5, as described previously [25].
Expression of markers for inflammation and gastric acid 
secretion
RNA was extracted from the third gastric tissue strip 
using the RNeasy Mini  Kit® (Qiagen, Hilden, Ger-
many), according to the manufacturer’s instructions. 
The obtained RNA concentrations were measured using 
a  NanoDrop® spectrophotometer (Isogen Life Science, 
Utrecht, The Netherlands), after which the concentra-
tion of each sample was adjusted to 1  μg/μL, followed 
by cDNA synthesis using the iScript™ cDNA Synthesis 
Kit (Bio-Rad, California, USA). Expression analysis was 
then performed for genes encoding host factors involved 
in gastric acid secretion (H+/K+ATPase, Sonic Hedge-
hog, KCNQ1, gastrin, the cholinergic muscarinic M3 
receptor, somatostatin, the histamine H2 receptor and 
the gastrin CCK-B receptor) and in inflammation (IL-
4, IL-6, IL-8, IL-10, IL-17, Il-1β, IFN-γ and TNFα). The 
housekeeping genes PPIa, H2afz and HPRT were shown 
to have a stable mRNA expression and therefore included 
as reference genes [26]. All primer sequences are shown 
in Additional file  1. The mRNA expression levels of the 
reference and target genes were quantified using a RT-
PCR, as described earlier [26]. No-template-control reac-
tion mixtures were included and all samples were run in 
duplicate. The  Ct-values were first normalized to the geo-
metric mean of the  Ct-values of the reference genes. Fold 
changes were calculated using ΔΔCT method with mean 
of  Ct-values from the control groups (groups 1 and 4). 
Finally, for each target gene, the results were expressed as 
fold changes of the mRNA expression of groups 2–4 and 
5–6 relative to mRNA expression levels of the H. suis-
negative control group and the H. suis-positive control 
group, respectively.
Gastric microbiota composition
DNA was extracted from the fourth gastric tissue strip 
using the DNeasy Blood & Tissue  Kit® (Qiagen) accord-
ing to the instructions of the manufacturer. 16S rRNA 
amplicon pyrosequencing was performed using the 
Roche GS-Junior Genome Sequencer as described pre-
viously by Rodriguez et al. [27]. The obtained 16S rRNA 
sequence reads were processed using MOTHUR (soft-
ware package v1.35), Pyronoise algorithm and UCHIME 
algorithm for alignment and clustering, denoising and 
chimera detection, respectively [28, 29]. The obtained 
read sets were compared to a reference dataset of 
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aligned sequences of the corresponding region derived 
from the SILVA database (v1.15) of full-length rRNA 
sequences implemented in MOTHUR [30]. The final 
reads were clustered into operational taxonomic units 
(OTUs) using the nearest neighbor algorithm using 
MOTHUR with a 0.03 distance unit cutoff. A taxonomic 
identity was attributed to each OTU by comparison 
with the SILVA database using a 80% homogeneity cut-
off. When a taxonomic identification lower than 80% 
was obtained, the taxonomic level was labelled with the 
first defined level from higher level followed by the label 
“unclassified”. Finally, the unique sequences for each 
OTU were compared with the SILVA data set using 
the BLASTN algorithm. For each OTU, a consensus 
taxonomic identification was given when less than 1% 
of mismatch with the aligned sequence was obtained. 
In the final metadata table, the following labelling was 
used: the population is identical to a taxonomically 
defined species and is labelled “genus_species”; the pop-
ulation is identical to a reference sequence belonging 
to a still undefined species and is labelled “genus_NCBI 
accession number”; the sequence is not identical to any 
known sequence and is labelled with the corresponding 
OTU number.
In order to determine the effect of H. suis and/or bam-
bermycin supplementation on the gastric microbiota 
composition, different groups were compared with each 
other:
(i) Helicobacter suis-negative mice without bambermy-
cin supplementation (i.e. group 1) (n = 5) vs H. suis-
negative mice with bambermycin supplementation 
(i.e. groups 2–3) (n = 7), H. suis-positive mice with-
out bambermycin supplementation (i.e. group 4) 
(n = 4) and H. suis-positive mice with bambermycin 
supplementation (n = 9) (i.e. groups 5–6).
(ii) Helicobacter suis-negative mice (i.e. groups 1–3) vs 
H. suis-positive mice (i.e. groups 4–6).
(iii) Mice without bambermycin supplementation (i.e. 
groups 1 and 4) vs mice with bambermycin sup-
plementation (i.e. groups 2–3 and 5–6).
Subsampled datasets were obtained and evaluated in 
MOTHUR to estimate the richness, microbial diversity 
and population evenness by using the Chao1 estima-
tor, Simpson’s reciprocal index and Simpson’s evenness 
index, respectively [31, 32]. Population structure and 
community membership were assessed with MOTHUR 
using distance matrix based on Bray–Curtis dissimilar-
ity index. Differences in functional profiles of gastric 
bacterial communities were analyzed by mapping taxa 
into several phenotypes (i.e. metabolism, Gram staining, 
sporulation,…) using  METAGENassist® [33]. Only the 
phenotypes detected in more than 50% of the samples 
were included for further analysis.
Statistical analysis
Statistical analysis was performed using SPSS statistics 
 24® (IBM, New York, USA). Differences in histopathol-
ogy and fold changes of the markers for gastric acid 
secretion and inflammation were investigated using 
the non-parametric Kruskal–Wallis test with Bonfer-
roni correction for multiple comparisons. Correlations 
between histopathology, fold changes and the number 
of H. suis bacteria were examined using the Pearson 
correlation coefficient. Differences were considered 
statistically significant at a corrected P value of less 
than 0.05.
Statistical differences in microbial diversity, richness 
and population evenness between the groups were inves-
tigated using non-parametric Kruskal–Wallis tests with 
Tukey post hoc tests using PRISM 7 (Graphpad Soft-
ware). Using MOTHUR, community composition dif-
ferences were investigated using Analysis of molecular 
variance (AMOVA) and homogeneity of molecular vari-
ance (HOMOVA). In order to highlight statistical differ-
ences in relative bacterial abundance between the groups, 
non-parametric Kruskal–Wallis tests with Tukey post 
hoc tests and Benjamini–Hochberg false discovery rate 
were performed using the STAMP software. Differences 
were considered statistically significant at a corrected P 
value of less than 0.05.
Results
MIC of bambermycin on H. suis strains
For all investigated H. suis strains, the MIC of bamber-
mycin was 8  μg/mL. For the reference strain S. aureus 
ATCC 29213 the MIC-value was 0.12 μg/mL when tested 
according to the method described by Butaye et  al. [21, 
22] and 0.5  μg/mL when tested according to the CLSI 
standards, while MIC-values of 1 and 2  μg/mL were 
obtained using the H. suis susceptibility assay conditions 
at pH 7 and 5, respectively.
Effect of bambermycin supplementation on H. suis 
colonization in mice
Non-H. suis infected groups 1, 2 and 3 tested nega-
tive for presence of H. suis as determined by qPCR and 
immunohistochemical staining, while all H. suis infected 
groups 4, 5 and 6 tested positive for H. suis. In both 
bambermycin-supplemented diet groups, the number of 
colonizing H. suis bacteria per mg gastric tissue as well 
as the colonization density was not altered compared to 
the H. suis-positive control group without bambermycin 
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supplementation (Additional file 2). In all H. suis infected 
groups, H. suis bacteria were often found in the lumen of 
the gastric glands and in close proximity of parietal cells 
(Additional file 3).
Effect of bambermycin supplementation on H. 
suis‑infection associated pathologies in mice
Inflammation
An overview of the defined immune cell populations of 
each group is shown in Figure 1.
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Figure 1 Scores for immune cells, apoptotic cells and parietal cells in bambermycin supplemented and non-supplemented groups. 
Scores for infiltration with inflammatory cells (A) and lymphoid follicle formation (B); number of infiltrating B-cells (C), T-cells (D), macrophages (E); 
number of apoptotic cells (F) and parietal cells (G) in bambermycin supplemented and non-supplemented groups. A, B Data are shown as the 
average scores for infiltration with inflammatory cells/lymphoid follicle formation, with standard deviation, of group 1–6. C–G Data are shown as 
the average number of positive cells per high power field (HPF), with standard deviation, belonging to a defined cell population, including B-cells, 
T-cells, macrophages, necrotic cells and parietal cells, of group 1–6. Statistical differences were calculated using the non-parametric Kruskal–Wallis 
H test SPSS statistics  24®. *Significant differences between the groups (P < 0.05), **significant differences between the groups (P < 0.005). Group 
1 = H. suis-negative control group without bambermycin supplementation; group 2 = 32 ppm bambermycin supplemented, non-H. suis infected 
group; group 3 = 64 ppm bambermycin supplemented, non-H. suis infected group; group 4 = H. suis-positive control group without bambermycin 
supplementation; group 5 = 32 ppm bambermycin supplemented, H. suis infected group; group 6 = 64 ppm bambermycin supplemented, H. suis 
infected group.
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The H. suis-positive control group 4 showed signifi-
cantly higher numbers of infiltrating B-cells and mac-
rophages compared to the H. suis-negative control group 
1 (P = 0.016 and 0.003, resp.) (Figure 2). Furthermore, a 
trend towards a higher number of infiltrating T-cells was 
seen in all H. suis infected groups 4–6 compared to the 
non-infected groups 1–3, although this was not signifi-
cant (Figures 1 and 2).
Compared to the H. suis-positive control group 4, a 
lower number of infiltrating B-cells and macrophages was 
demonstrated in the 32 ppm bambermycin supplemented, 
H. suis infected group 5 (P = 0.068 and 0.001, resp.) as well 
as in the 64  ppm bambermycin supplemented, H. suis 
infected group 6 (P = 0.003 and 0.005, resp.) (Figure 2). In 
comparison to both groups that did not receive bamber-
mycin (groups 1 and 4), all bambermycin-supplemented 
diet groups showed significantly lower scores for infiltra-
tion with inflammatory cells as well as infiltrating T-cells 
(P < 0.005 and < 0.001, resp.) (Figures 1 and 2). No signifi-
cant differences were detected in the formation of lym-
phoid follicles between the groups.
The infiltration with inflammatory cells was positively 
correlated with the number of infiltrating T-cells and 
macrophages, while the number of infiltrating T-cells 
was positively correlated with the number of infiltrating 
B-cells and macrophages (Additional file 4). No correla-
tions were found between the number of inflammatory 
cells and the number of colonizing H. suis bacteria per 
mg gastric tissue.
Positive correlations were found between the number 
of infiltrating macrophages and the expression of IL-8Kc, 
IL-8Li, IL-10, IL-17, IFN-γ, TNF-α and IL-1β; between 
the number of infiltrating T-cells and the expression of 
IL-8Li, IL-10 and IL-1β and between the number of infil-
trating B-cells and the expression of IL-4, IL-10 and IL-12 
(Additional file 4).
Gastric epithelial cell proliferation and death
An overview of the defined cell populations of each group 
is shown in Figure 1.
The H. suis-positive control group 4 showed signifi-
cantly lower numbers of parietal cells compared to the 
H. suis-negative control group 1 (P = 0.032) (Figures  1 
and 2). The 64 ppm bambermycin supplemented, H. suis-
infected group 6, however, showed significantly higher 
numbers of parietal cells compared to the H. suis-positive 
control group 4 (P = 0.038). This was also the case for the 
32  ppm bambermycin supplemented, H. suis infected 
group 5, although not significant. The number of apop-
totic cells and epithelial cell proliferation did not differ 
between the groups.
Negative correlations were detected between the num-
ber of parietal cells and the number of infiltrating T-cells, 
B-cells, macrophages and inflammatory cells in general 
(Additional file 4).
Effect of bambermycin supplementation on the expression 
of markers for inflammation
The fold changes of altered markers for inflammation are 
represented in Figure 3 and Additional file 5.
The H. suis-positive control group 4 showed upregu-
lated expressions of IL-4, IL-6, IL-8M, IL-8Li, IL-10, and 
TNF-α compared to the H. suis-negative control group 
1 (P = 0.091, 0.115, 0.298, 0.002, 0.012 and 0.065, resp.). 
In addition, IL-17 and IL-23 were significantly down-
regulated (P < 0.001) (Additional file  5, Figure  3). Both 
bambermycin supplemented, H. suis infected groups 5 
and 6 showed upregulated expressions of IL-4, IL-6 and 
IL-8Li in comparison with the H. suis-negative con-
trol group 1 (fold change = 3.24 ± 0.89, 2.95 ± 0.64 and 
3.25 ± 0.54; P = 0.118, 0.066 and 0.002, resp. for group 
5; fold change = 1.71 ± 0.48, 2.38 ± 0.51 and 3.44 ± 1.03; 
P = 0.970, 0.066 and 0.015, resp. for group 6), while 
IL-17 and IL-23 transcript levels were downregulated 
(fold change = 0.05 ± 0.02 and 0.15 ± 0.05; P < 0.001 
and < 0.001, resp. for group 5; fold change = 0.03 ± 0.01 
and 0.22 ± 0.07; P < 0.001 and = 0.001, resp. for group 6). 
The expression of TNF-α, however, was not altered dur-
ing bambermycin supplementation in the H. suis infected 
groups 5 and 6 in comparison with the H. suis-negative 
control group 1. Since positive correlations were found 
between both, the altered fold changes of IL-4, IL-8Li, 
IL-17 and IL-23 were more pronounced in mice with a 
higher number of colonizing H. suis bacteria per mg gas-
tric tissue (Additional file 4).
Compared to the H. suis-positive control group 4, the 
mRNA expressions of IL-8M and IFN-γ were down-
regulated in the 32  ppm bambermycin supplemented, 
H. suis infected group 5 (P = 0.100 and 0.015, resp.), as 
well as the IL-8M, IL-10 and IFN-γ transcript levels in 
the 64 ppm bambermycin supplemented, H. suis infected 
group 6 (P = 0.001, 0.077, 0.253, resp.).
In both bambermycin supplemented, H. suis-negative 
groups 2 and 3, the expression of IL-1β was significantly 
downregulated compared to the H. suis-negative control 
group 1 (P = 0.028 and 0.015, resp.). A similar obser-
vation was found for the 64  ppm bambermycin sup-
plemented, H. suis-positive group compared to the H. 
suis-negative control group (fold change = 0.72 ± 0.13; 
P = 0.065).
Effect of bambermycin supplementation on the expression 
of markers for gastric acid secretion
The fold changes of altered markers for gastric acid secre-
tion are presented in Figure 4 and Additional file 6.
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Figure 2 Microscopic visualization of immune cells, apoptotic cells, proliferative cells and parietal cells in the mouse stomach. A, B 
HE-staining showing infiltration with mononuclear and polymorphonuclear cells in H. suis infected mice without (A) and with bambermycin (B) 
supplementation. The infiltration is less severe during bambermycin supplementation. Original magnification: ×400. C, D CD3-staining showing 
infiltration with T-cells (brown) in H. suis infected mice without (C) and with bambermycin (D) supplementation. The infiltration is less severe during 
bambermycin supplementation. Original magnification: ×400. E, F CD20-staining showing infiltration with B-cells (dark brown) in mice infected 
with (E) and without H. suis (F). The infiltration is more severe during H. suis infection. Original magnification: ×400. G, H F4/80 staining showing 
infiltration with macrophages (brown) in mice infected with (G) and without (H) H. suis. The infiltration is more severe during H. suis infection. Origi-
nal magnification: ×400. I, J H+/K+ATPase-staining showing parietal cells (brown) in mice infected with (I) and without (J) H. suis. The number of 
parietal cells is lower during H. suis infection. H. suis bacteria can be seen in the lumen of the gastric glands (arrow). Original magnification: ×400.
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In summary, the H. suis-positive control group 4 
showed upregulated expressions of KCNQ1 and the 
CCK-B receptor in comparison with the H. suis-negative 
control group 1 (P = 0.119 and 0.032, resp.). In addi-
tion, the bambermycin supplemented groups 2–3 and 5 
showed upregulated expressions of H+/K ATPase, Sonic 
Hedgehog, KCNQ1, M3 receptor and/or CCK-B receptor 
in comparison with the H. suis-negative and/or positive 
control groups 1 and 4 (Figure 4, Additional file 6).
Positive correlations were found between the altered 
expressions of KCNQ1, CCK-B receptor and somato-
statin and the expressions of IL-8 and IL-10 (Additional 
file 4).
Effect of bambermycin supplementation and/or H. suis 
infection on the gastric microbiota composition in mice
Despite several attempts, including altering the number 
of pyrosequencing cycles, no sequencing reads could be 
obtained from three mice of the H. suis-negative con-
trol group 1; 5 of group 2; 4 of group 3; 4 of group 4; 4 of 
group 5 and 3 of group 6. The other 25 samples yielded 
sufficient reads after pyrosequencing and were selected 
for further analysis. Pyrosequencing yielded between 400 
and 4000 reads per sample (Additional file 7). A total of 
70  118 final reads were attributed to 1290 species level 
OTUs for the 25 samples. Chimeric sequences repre-
sented 20% of the total sequencing reads and were thus 
excluded from the analysis.
In general, total bacterial community analysis showed 
that the most dominant phylum in the murine stom-
ach was Firmicutes contributing up to 92%, followed by 
Bacteroides (4%) and Proteobacteria (4%). The relative 
abundance of other phyla was below 0.1%. On the family 
level, following populations (i.e. > 0.5%) were dominant 
in the murine stomach: Lactobacillaceae (63%), Clostri-
diaceae (9%), Erysipelotrichaceae (6%), Streptococcaceae 
(4%) and Porphyromonadaceae (4%). The major genera 
(i.e. > 0.5%) were Lactobacillus (63%), Clostridium sensu 
stricto (9%), unclassified Erysipelotrichaceae (5%), Lacto-
coccus (4%), Parabacteroides (4%) and Turicibacter (2%). 
In two bambermycin supplemented, H. suis-positive mice 
(i.e. one of the 32 ppm supplemented group 5 and one of 
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Figure 3 General overview of relative fold changes of altered markers for inflammation in the bambermycin-supplemented and non-
supplemented groups. The data are presented as fold changes in gene expression normalized to 3 reference genes and relative to control groups 
1 and 4 (i.e. group 2–4 relative to group 1 and group 5–6 relative to group 4) which are considered as 1. The fold changes are shown as means with 
the standard error of the mean. Statistical differences were calculated using the non-parametric Kruskal–Wallis H test SPSS statistics  24®. *Signifi-
cant differences with the control group (P < 0.05), **significant differences with the control group (P < 0.005). Group 1 = H. suis-negative control 
group without bambermycin supplementation; group 2 = 32 ppm bambermycin supplemented, non-H. suis infected group; group 3 = 64 ppm 
bambermycin supplemented, non-H. suis infected group; group 4 = H. suis-positive control group without bambermycin supplementation; group 
5 = 32 ppm bambermycin supplemented, H. suis infected group; group 6 = 64 ppm bambermycin supplemented, H. suis infected group.
Page 10 of 16De Witte et al. Vet Res  (2018) 49:35 
the 64 ppm supplemented group 6), however, Proteobac-
teria represented the major phylum (97%). Helicobacte-
riaceae (11%) and Helicobacter (11%) also represented 
dominant populations in the murine stomach, but only in 
the H. suis-positive groups 4–6. The average gastric bac-
terial community composition at the phylum, family and 
genus level present in the different groups is represented 
in Figures 5A–C, while the bacterial community compo-
sition of each individual mice is shown in Additional files 
8 A–C.
Bambermycin supplementation and/or infection with 
H. suis had no effect on microbial diversity, richness and 
population evenness (Additional files 9 A–C). Further-
more, Unifrac weighted analysis as well as AMOVA and 
HOMOVA did not reveal significant differences regard-
ing community structure and composition of the groups. 
Population structure and community membership, as 
determined by Bray–Curtis dissimilarity index, was also 
not different between the groups.
Phenotypic analysis of the murine gastric microbiota 
in general revealed the presence of 12 metabolic phe-
notypes of which ammonia oxidizer, dehalogenation, 
chitin degradation, xylan degrader, sulfide oxidizer and 
dinitrogen-fixing were the most abundant, each account-
ing for 78, 78, 14, 7, 7 and 6% of the gastric bacterial com-
munity, respectively. In the gastric microbiota of all mice, 
non-sporulating and Gram-positive bacteria were more 
abundant than sporulating and Gram-negative bacteria, 
respectively (70% vs 10% and 72% vs 0.5%, respectively). 
Presence of H. suis infection did not influence the phe-
notypic features of the gastric bacterial community. The 
bambermycin supplemented groups, however, showed 
significant lower abundance of sporulating and chitin 
degrading bacteria compared to the groups without bam-
bermycin supplementation (3.0% vs 19.7%, P = 0.027 and 
7.9% vs 23.7%, P = 0.027, respectively).
The taxa Helicobacteriaceae, Helicobacter and H. suis 
at family, genus and species level, respectively, were only 
present in the H. suis infected groups (11%, P < 0.05). 
Infection with H. suis did not influence the relative abun-
dance of other taxa at phylum, family or genus level. At 
species level, Christensenella sp. EF603775 was only 
present in the H. suis–negative mice (0.041%), although 
this difference was not significant (P = 0.223). In general, 
mice that received bambermycin (i.e. groups 2, 3, 5 and 6) 
showed a relative lower abundance of the following taxa:
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Figure 4 General overview of relative fold changes of altered markers for gastric acid secretion in the bambermycin-supplemented 
and non-supplemented groups. The data are presented as fold changes in gene expression normalized to 3 reference genes and relative to con-
trol groups 1 and 4 (i.e. group 2–4 relative to group 1 and group 5–6 relative to group 4) which are considered as 1. The fold changes are shown as 
means with the standard error of the mean. Statistical differences were calculated using the non-parametric Kruskal–Wallis H test SPSS statistics  24®. 
*Significant differences with the control group (P < 0.05), **significant differences with the control group (P < 0.005). Group 1 = H. suis-negative con-
trol group without bambermycin supplementation; group 2 = 32 ppm bambermycin supplemented, non-H. suis infected group; group 3 = 64 ppm 
bambermycin supplemented, non-H. suis infected group; group 4 = H. suis-positive control group without bambermycin supplementation; group 
5 = 32 ppm bambermycin supplemented, H. suis infected group; group 6 = 64 ppm bambermycin supplemented, H. suis infected group.
Page 11 of 16De Witte et al. Vet Res  (2018) 49:35 
 – At phylum family, genus and species level: Firmicutes_
unclassified.
  – At phylum, family and genus level: Bacteria_unclassi-
fied.
  – At family level: Clostridiaceae_1.
  – At genus level: Clostridiaceae_1_unclassified, Coproc-
occus, Turicibacter, Clostridium_sensu_stricto_1.
 – At species level: Coprococcus_EF099198, Coprococcus_ 
16S_OTU119, Clostridiales_Family_XIII_AB702776, 
Clostridiales_Family_XIII_16S_OTU162, Clostridi-
Figure 5 Average gastric bacterial community compositions present in the bambermycin-supplemented and non-supplemented 
groups. The cumulated histograms show the relative abundance of the identified taxa at phylum (A), family (B) or genus (C) level. At family and 
genus level, taxa with a relative abundance < 1% are merged in the category “others”. Group 1 = H. suis-negative control group without bambermy-
cin supplementation; group 2 = 32 ppm bambermycin supplemented, non-H. suis infected group; group 3 = 64 ppm bambermycin supplemented, 
non-H. suis infected group; group 4 = H. suis-positive control group without bambermycin supplementation; group 5 = 32 ppm bambermycin sup-
plemented, H. suis infected group; group 6 = 64 ppm bambermycin supplemented, H. suis infected group. The unclassified populations correspond 
to defined groups of the genus level for which a taxonomical classification assignation to the genus cannot be attributed. These populations are 
therefore labelled with the first defined superior hierarchical taxonomic level followed by “_unclassified” to prevent confusion.
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ales_Family_XIII_EF604613, Clostridiaceae_1_16S_
OTU75, Clostridiaceae_1_16S_OTU107, Firmicutes_ 
16S_OTU195, Firmicutes_16S_OTU37, Firmicutes_ 
16S_OTU43, Firmicutes_16S_OTU594, Turicibacter_ 
EF406660, Turicibacter_DQ015666 and Turicibacter_
EF406615 (Additional file 10).
The relative abundance of these taxa did not differ 
between the groups receiving different doses of in-feed 
bambermycin medication.
Interestingly, the relative abundance of these taxa was 
positively correlated with infiltration with inflamma-
tory cells, T-cells, B-cells and macrophages as well as 
the expression of IFN-γ, gastrin and somatostatin, while 
negatively correlated with the number of parietal cells 
and the expression of H2 receptor, CCK-B receptor, H+/
K+ATPase and KCNQ1 (Additional file 11).
Discussion
In the present study, an infection with H. suis elicited 
increased infiltration with inflammatory cells such as 
B-cells, macrophages and T-cells. These findings are in 
line with previous studies where H. suis infection was 
associated with development of severe gastritis in experi-
mentally and naturally infected pigs and experimentally 
infected mice and Mongolian gerbils [17, 34, 35]. Since 
macrophages produce several factors, such as IL-10, 
which provoke a Th2 response [36] and since B-cells pro-
mote the expansion of Th2 cells [37], infiltration with 
these inflammatory cells may have contributed to the 
observed Th2 response in H. suis infected mice.
The expression of IL-17, however, was downregulated 
in the H. suis infected mice, in contrast with other studies 
where a clear IL-17 upregulation and a mixed Th2/Th17 
response was present in H. suis infected mice [17, 26, 34, 
38, 39]. This might be caused by the absence of an IL-23 
upregulation, a cytokine stimulating Th17 cell expan-
sion [40]. As Flahou et al. showed an inverse correlation 
between the H. suis colonization rate and the expression 
of IL-17 [26], the observed high number of colonizing H. 
suis bacteria per mg gastric tissue might have contributed 
to the downregulation of IL-17. Still, it is not clear why a 
Th17 response was absent in this study.
BALB/c mice experimentally infected with H. pylori 
and C57BL/6 mice experimentally infected with H. felis, 
showed a decreased number of Lactobacillus spp. and an 
increased number of Clostridium spp., Bacteroides spp., 
Prevotella spp., Eubacterium spp., Ruminococcus spp., 
Streptococcus spp. and E. coli in their stomach [41, 42]. In 
another study, however, H. pylori infected C57BL/6 mice 
did not show gastric microbiota alterations [43]. In the 
present study, H. suis infection was not associated with 
a shift in the gastric microbiota. Often, the used mouse 
substrain is not mentioned and although the same strain 
can be used in different studies, the substrain may be 
different. These differences in genetic background may 
contribute to discrepancies between studies [44]. Dif-
ferences in virulence between Helicobacter sp., stage of 
infection, and/or influence of the host immune response 
may also contribute to the discrepancies [45]. In future 
studies, it would be interesting to investigate a more long 
term effect of a H. suis infection on the gastric microbiota 
composition.
Since H. suis only grows in a biphasic medium with an 
acidic pH, standard antimicrobial susceptibility assays 
cannot be used for MIC determinations. The use of the 
combined agar and broth dilution method [20] may have 
influenced the results, as Butaye et  al. demonstrated 
that medium composition has a clear impact on bam-
bermycin activity [22]. For example, addition of sheep 
blood, hemoglobin, albumin, casein and starch as well as 
variations in pH and inoculum size affect the activity of 
bambermycin in vitro [10, 22]. Although for MIC deter-
minations, a strict standardization of the test medium is 
preferable [22], no optimal medium exists to test bam-
bermycin susceptibility of fastidious micro-organisms, 
such as H. suis. In comparison with the method described 
by Butaye et al. [22], the MIC endpoints of the reference 
strain S. aureus ATCC 29213 were 2, 3 and 4 times higher 
when using the broth microdilution procedure accord-
ing to CLSI standards and the H. suis susceptibility assay 
conditions at pH 5 and 7, respectively. The presence of 
dextrose, casein and/or other components in Brucella 
broth may have contributed to the decreased activity of 
bambermycin.
To the best of our knowledge, no susceptibility data of 
bambermycin on H. suis has been published. In the pre-
sent study, all H. suis strains showed a MIC-value of 8 μg/
mL. Despite this relatively low MIC endpoint, bamber-
mycin supplementation did not affect the H. suis coloni-
zation rate in vivo. As no specific clinical breakpoints for 
bambermycin against H. suis are available, prediction of 
the clinical efficacy based on in vitro testing solely is dif-
ficult. This is further complicated by the fact that, even 
in  vitro, different components in the medium such as 
proteins, starch and lipid substances, may highly influ-
ence the antibacterial activity of bambermycin [22]. 
The gastric environment is far more complex than this 
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in  vitro environment, making it almost impossible to 
predict the activity of bambermycin in the stomach from 
results of MIC determinations.
Despite the absence of an effect on the H. suis coloni-
zation rate, parietal cell loss during H. suis infection was 
countered when bambermycin was supplemented. A 
decreased parietal cell mass has also been shown in H. 
suis infected BALB/c mice and Mongolian gerbils [17, 
35]. It has been postulated that the loss of parietal cells 
might be due to a direct interaction of H. suis with these 
cells, since the bacterium can cause degenerative changes 
and necrosis of parietal cells in pigs, humans and rodent 
models [17, 46] and H. suis is able to directly interfere 
with cultured parietal cells, causing a significant impair-
ment in cell viability [47]. Production of γ-glutamyl trans-
peptidase (GGT) by H. suis has been linked with these 
degenerative changes and/or impairment in cell viability 
[35]. It remains to be determined if bambermycin affects 
this direct interaction of the bacterium with parietal cells, 
without influencing its colonization capacity. The inverse 
correlation seen in the present and other studies [47], 
between severity of gastric inflammation and the number 
of parietal cells indicates that not only direct interaction 
of this bacterium with these host cells, but also inflam-
mation may play a role in parietal cell death in H. suis 
infected hosts.
Several studies attribute a role to H. suis in the develop-
ment of hyperkeratosis and ulceration of the non-glandu-
lar stratified squamous epithelium of the Pars oesophagea 
of the porcine stomach, although H. suis does not colo-
nize this region [4]. It is not completely clear how exactly 
H. suis influences ulcer development, but a recent study 
indicates that alterations in gastric acid secretion may be 
involved [3]. Indeed, in H. suis infected 6–8 months old 
pigs with severe hyperkeratosis and erosions of the non-
glandular part of the stomach, expression of markers for 
gastric acid secretion was downregulated. It was hypoth-
esized that decreased gastric acid secretion may affect the 
composition of the Pars oesophageal microbiota. Indeed, 
compared to non-infected, 6–8 months old pigs with no 
obvious lesions, higher numbers of Fusobacterium gas-
trosuis [48], were detected in the Pars oesophagea of H. 
suis infected pigs with hyperkeratosis and erosions of 
the Pars oesophagea and downregulated markers for gas-
tric acid secretion. In the present study, bambermycin 
supplementation resulted in an upregulation of several 
markers for gastric acid secretion and seemed to coun-
ter the parietal cell mass loss during H. suis infection. It 
remains to be determined if bambermycin affects gastric 
ulcer development in H. suis infected pigs.
Although an improved feed conversion and growth 
has been demonstrated in pigs, cattle and poultry during 
bambermycin supplementation, the effect on gastro-
intestinal inflammation had not been investigated before 
[49–52]. Here, the increased infiltration with mac-
rophages, T-cells and B-cells and upregulated expressions 
of IL-8M, IL-10, TNF-α and IFN-γ in H. suis infected mice 
was countered when bambermycin was supplemented in 
the diet, even though this antibiotic apparently did not 
influence H. suis colonization. Similarly, in the stomach 
of the non-H. suis infected mice treated with bambermy-
cin, a decreased T-cell and macrophage infiltration was 
observed as well as a downregulated expression of the 
pro-inflammatory cytokine IL-1β, further indicating that 
bambermycin may alter the function of inflammatory cells 
resulting in a more tempered host immune response. The 
mechanism behind this anti-inflammatory effect is not 
clear. It has been hypothesized that macrolides, cyclines 
and streptogramins may accumulate in phagocytic cells, 
reducing the production of pro-inflammatory cytokines 
[53]. Macrolides may also inhibit T-cell maturation and 
proliferation [54]. It is not known if similar mechanisms 
are involved for bambermycin.
In the present study, bambermycin supplementation 
did not cause major shifts in Lactobacillus spp., which 
have been considered to exert a beneficial effect in the 
intestinal tract [10]. On the other hand, the presence of 
bacterial species belonging to Firmicutes, Turicibacter, 
Coprococcus, Clostridiaceae, Clostridiales family XIII 
and Clostridium senso stricto 1 taxa was positively cor-
related with infiltration of inflammatory cells as well as 
expression of markers for inflammation. This might indi-
cate that some bacteria belonging to these taxa might 
exert unfavorable effects on the host. Since the relative 
abundance of these taxa was decreased during bamber-
mycin supplementation, an altered gastric microbiota 
composition may also have contributed to the anti-
inflammatory effect of bambermycin. Nevertheless, as 
most of these species are yet unknown, further research 
is necessary to confirm or deny this hypothesis. Finally, 
ammonia oxidizers accounted for 78% of the gastric bac-
terial community. These bacteria produce nitric oxide, 
which may exert damaging effects and contribute to 
gastritis. It has been shown that bambermycin exhibits 
an anti-oxidative effect by scavenging free nitric oxide 
radicals in  vitro [55], which may also play a role in the 
observed anti-inflammatory effect of in-feed bambermy-
cin medication.
In conclusion, bambermycin supplementation did 
not affect H. suis colonization, but did decrease gastric 
inflammation and inhibited the effects of a H. suis infec-
tion on parietal cell loss. Not only direct interaction of H. 
suis with parietal cells, but also inflammation may play a 
role in death of these gastric acid producing cells.
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Additional file 1. List of primers used in quantitative RT-PCR for 
gene expression analysis of markers for gastric acid secretion and 
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Additional file 2. Number and colonization density of H. suis in 
groups 4-6. (A) Number of H. suis bacteria per mg gastric tissue of group 
4-6. Data are shown as log10 values of the average of number of H. suis 
bacteria per mg tissue with standard deviation. (B) Colonization density 
of H. suis in the stomach of group 4-6. Data are shown as the average of 
the colonization score for each group with standard deviation. Group 
4 = H. suis-positive control without bambermycin supplementation; group 
5 = 32 ppm bambermycin supplemented, H. suis infected group; group 
6 = 64 ppm bambermycin supplemented, H. suis infected group.
Additional file 3. Immunohistochemical Helicobacter (A), caspase-3 
(B) and KI-67 (C) staining of a mouse stomach, showing H. suis 
colonization, apoptotic cells and replicating cells, respectively. (A) 
H. suis bacteria (brown) present in the glands of the antrum of a stomach 
of a H. suis-positive control mouse not treated with bambermycin. Original 
magnification: ×400. (B) Apoptotic cells (brown) present in a stomach of a 
H. suis-negative mouse treated with bambermycin. Original magnification: 
×400. (C) Replicating cells (brown) present in a stomach of a H. suis-
negative mouse treated with bambermycin. Original magnification: ×400.
Additional file 4. Overview of important correlations. r = Pearson 
correlation coefficient, calculated using SPSS Statistics  24®. A r-value 
close to 1 indicates a strong, positive correlation, whereas a r-value of 
-1 indicates a strong, negative correlation. P-values lower than 0.05 are 
considered to be significant.
Additional file 5. Overview of the relative fold changes of altered 
markers for inflammation in the bambermycin-supplemented and 
non-supplemented groups. The data are presented as fold changes in 
gene expression normalized to 3 reference genes and relative to control 
groups 1 and 4 (i.e. group 2-4 relative to group 1 and group 5-6 relative 
to group 4) which are considered as 1. The fold changes are shown as 
means with the standard error of the mean. Statistical differences were 
calculated using the non-parametric Kruskal–Wallis H test SPSS statistics 
 24®. A P-value lower than 0.05 is considered to be significant. Group 
2 = 32 ppm bambermycin supplemented, non-H. suis infected group; 
group 3 = 64 ppm bambermycin supplemented, non-H. suis infected 
group; group 4 = H. suis-positive control group without bambermycin 
supplementation; group 5 = 32 ppm bambermycin supplemented, H. suis 
infected group; group 6 = 64 ppm bambermycin supplemented, H. suis 
infected group.
Additional file 6. Overview of the relative fold changes of altered 
markers for gastric acid secretion in the bambermycin-supple-
mented and non-supplemented groups. The data are presented as 
fold changes in gene expression normalized to 3 reference genes and 
relative to control groups 1 and 4 (i.e. group 2-4 relative to group 1 and 
group 5-6 relative to group 4) which are considered as 1. The fold changes 
are shown as means with the standard error of the mean. Statistical dif-
ferences were calculated using the non-parametric Kruskal–Wallis H test 
SPSS statistics  24®. A P-value lower than 0.05 is considered to be signifi-
cant. Group 2 = 32 ppm bambermycin supplemented, non-H. suis infected 
group; group 3 = 64 ppm bambermycin supplemented, non-H. suis 
infected group; group 4 = H. suis-positive control group without bamber-
mycin supplementation; group 5 = 32 ppm bambermycin supplemented, 
H. suis infected group; group 6 = 64 ppm bambermycin supplemented, H. 
suis infected group.
Additional file 7. Overview of the number of pyrosequencing 
reads for each mice. Group 1 = H. suis-negative control group without 
bambermycin supplementation; group 2 = 32 ppm bambermycin sup-
plemented, non-H. suis infected group; group 3 = 64 ppm bambermycin 
supplemented, non-H. suis infected group; group 4 = H. suis-positive 
control group without bambermycin supplementation; group 5 = 32 ppm 
bambermycin supplemented, H. suis infected group; group 6 = 64 ppm 
bambermycin supplemented, H. suis infected group.
Additional file 8. Bacterial community compositions present in the 
stomach of each individual mice. The cumulated histograms show the 
relative abundance of the identified taxa at phylum (A), family (B) or genus 
(C) level. At family and genus level, taxa with a relative abundance < 1% 
are merged in the category “others”. M1_ = group 1 = H. suis-negative 
control group without bambermycin supplementation; M2_ = group 
2 = 32 ppm bambermycin supplemented, non-H. suis infected group; 
M3_ = group 3 = 64 ppm bambermycin supplemented, non-H. suis 
infected group; M4_ = group 4 = H. suis-positive control group without 
bambermycin supplementation; M5_ = group 5 = 32 ppm bambermycin 
supplemented, H. suis infected group; M6_ = group 6 = 64 ppm bamber-
mycin supplemented, H. suis infected group. The unclassified populations 
correspond to defined groups of the genus level for which a taxonomical 
classification assignation to the genus cannot be attributed. These popu-
lations are therefore labelled with the first defined superior hierarchical 
taxonomic level followed by “_unclassified” to prevent confusion.
Additional file 9. Overview of the gastric bacterial richness, 
diversity and evenness of the bambermycin-supplemented and 
non-supplemented groups. Gastric bacterial richness (A), diversity (B) 
and evenness (C). The data are represented as box plots: the bottom and 
top of the box represent the first and the third quartile, the line in the 
box represents the median and the whiskers represent the minimum 
and maximum values. Group 1 = H. suis-negative control group without 
bambermycin supplementation; group 2 = 32 ppm bambermycin sup-
plemented, non-H. suis infected group; group 3 = 64 ppm bambermycin 
supplemented, non-H. suis infected group; group 4 = H. suis-positive 
control group without bambermycin supplementation; group 5 = 32 ppm 
bambermycin supplemented, H. suis infected group; group 6 = 64 ppm 
bambermycin supplemented, H. suis infected group.
Additional file 10. An overview of the main differences in relative 
abundance of taxa at phylum, family, genus and species level in 
the bambermycin-supplemented and non-supplemented groups. 
The data are presented as the mean relative abundance of the taxa with 
the standard error of the mean. Statistical differences were calculated 
using the non-parametric Kruskal–Wallis tests with Tukey post hoc tests 
and Benjamini–Hochberg False Discovery Rate were performed using 
 STAMP®. A P-value lower than 0.05 is considered to be significant.
Additional file 11. Overview of important correlations between 
the gastric bacterial community and the number of inflammatory 
cells, parietal cells and expression of markers for inflammation and 
gastric acid secretion. r = Pearson correlation coefficient, calculated 
using SPSS Statistics  24®. A r-value close to 1 indicates a strong, positive 
correlation, whereas a r-value of -1 indicates a strong, negative correlation. 
P-values lower than 0.05 are considered to be significant.
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